Tissue factor pathway inhibitor release and depletion by sulodexide in humans

Advances in Medical Sciences

Volumn 54, Issue 1, 2009, Pages

  Borawski, J ^a   Gozdzikiewicz, J ^a   Dubowski, M ^a   Pawlak, K ^a   Mysliwiec, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Glycosaminoglycan; Human study; Sulodexide; tissue factor pathway inhibitor

Indexed keywords

SULODEXIDE; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VESSEL DUE F; ANTICOAGULANT AGENT; GLYCOSAMINOGLYCAN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ADULT; ANTIGEN DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PILOT STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT DURATION; ANALYSIS OF VARIANCE; BLOOD; BLOOD CLOTTING TEST; METABOLISM; REGRESSION ANALYSIS; TIME;

ADULT; ANALYSIS OF VARIANCE; ANTICOAGULANTS; BLOOD COAGULATION TESTS; GLYCOSAMINOGLYCANS; HUMANS; LIPOPROTEINS; MALE; PILOT PROJECTS; REGRESSION ANALYSIS; TIME FACTORS;

EID: 66149157790     PISSN: 18961126     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10039-009-0009-4     Document Type: Article

References (22)

1. Lauver D. A. Lucchesi B. R. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev. 2006 Fall-Winter; 24 (3-4): 214-26. (Pubitemid 46435004)
2. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan; 18 (1): 1-20. (Pubitemid 28037477)
3. Ofosu F. A. Pharmacological actions of sulodexide. Semin Thromb Hemost. 1998; Feb 424 (2): 127-38. (Pubitemid 28180822)
4. Abaterusso C. Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol. 2006 Apr; 5 (4): 211-22. (Pubitemid 44166672)
5. Gozdzikiewicz J. Borawski J. Mysliwiec M. Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost. 2009 Feb; 15 (1): 92-7.
6. Liaw P. C. Becker D. L. Stafford A. R. Fredenburgh J. C. Weitz J. I. Molecular basis for the susceptibility of fbrinbound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem. 2001 Jun; 276 (24): 20959-65. (Pubitemid 37413076)
7. Linhardt R. J. Al-Hakim A. Liu J. A. Hoppensteadt D. Mascellani G. Bianchini P. Fareed J. Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol. 1991 Sep. 27; 42 (8): 1609-19.
8. Hoppensteadt D. A. Walenga J. M. Fasanella A. Jeske W. Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res. 1995 Jan 15; 77 (2): 175-85.
9. Lupu C. Poulsen E. Roquefeuil S. Westmuckett A. D. Kakkar V. V. Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1999 Sep; 19 (9): 2251-62. (Pubitemid 29422260)
10. Bendz B. Hansen J. B. Andersen T. O. Ostergaard P. Sandset P. M. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Br J Haematol. 1999 Dec; 107 (4): 756-62. (Pubitemid 30020146)
11. Hansen J. B. Sandset P. M. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic effcacy. Thromb Res. 1998 Aug. 15; 91 (4): 177-81. (Pubitemid 28429586)
12. Hansen J. B. Sandset P. M. Huseby K. R. Huseby N. E. Nordøy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost. 1996 Nov; 76 (5): 703-9. (Pubitemid 26388173)
13. Crawley J. T. Lane D. A. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008 Feb; 28 (2): 233-42.
14. Sandset P. M. Abildgaard U. Larsen M. L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 1988 Jun. 15; 50 (6): 803-13. (Pubitemid 18185759)
15. Alban S. Molecular weight-dependent infuence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Semin Thromb Hemost. 2001 Oct; 27 (5): 503-11. (Pubitemid 32989375)
16. Ma Q. Tobu M. Schultz C. Jeske W. Hoppensteadt D. Walenga J. Cornelli U. Lee J. Linhardt R. Hanin I. Fareed J. Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thromb Res. 2007 Feb; 119 (5): 653-61. (Pubitemid 46304069)
17. Naumnik B. Borawski J. Mysliwiec M. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis. Nephrol Dial Transplant. 2003 Jul; 18 (7): 1376-82. (Pubitemid 36826960)
18. Novotny W. F. Brown S. G. Miletich J. P. Rader D. J. Broze G. J. Jr. Plasma antigen levels of the lipoproteinassociated coagulation inhibitor in patient samples. Blood. 1991 Jul. 15; 78 (2): 387-93.
19. Salbach P. B. Brückmann M. Turovets O. Kreuzer J. Kübler W. Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol. 2000 Sep; 50 (3): 221-6.
20. Borawski J. Dubowski M. Pawlak K. Mysliwiec M. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007 Mar; 558 (1-3): 167-71. (Pubitemid 46328890)
21. Borawski J. Dubowski M. Pawlak K. Mysliwiec M. Effect of sulodexide on plasma transforming growth factorbeta1 in healthy volunteers. Clin Appl Thromb Hemost. 2008 doi: 10.1177/1076029608326170.
22. Borawski J. Zbroch E. Rydzewska-Rosolowska A. Pawlak K. Mysliwiec M. Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II. J Nephrol. 2007 May-Jun; 20 (3): 370-2. (Pubitemid 47570369)